$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019917 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$50.00K	$40.00K	$65.00K
YoY Change	19.05%	-18.37%	16.07%
Cost Of Revenue	$8.000K	$8.000K	$12.00K
YoY Change
Gross Profit	$42.00K	$32.00K	$53.00K
YoY Change	0.0%	-34.69%	-5.36%
Gross Profit Margin	84.0%	80.0%	81.54%
Selling, General & Admin	$2.717M	$3.916M	$10.86M
YoY Change	6.55%	70.86%	209.76%
% of Gross Profit	6469.05%	12237.5%	20484.91%
Research & Development	$1.145M	$1.951M	$3.200M
YoY Change	-61.23%	-4.92%	51.87%
% of Gross Profit	2726.19%	6096.88%	6037.74%
Depreciation & Amortization	$61.00K	$9.000K	$58.00K
YoY Change	-23.75%	-18.18%	-65.88%
% of Gross Profit	145.24%	28.13%	109.43%
Operating Expenses	$1.145M	$1.951M	$14.06M
YoY Change	-61.23%	-4.92%	150.48%
Operating Profit	-$3.694M	-$5.734M	-$14.00M
YoY Change	-32.36%	33.5%	152.05%
Interest Expense	$179.0K	$72.00K	$659.0K
YoY Change		-82.09%	55.79%
% of Operating Profit
Other Income/Expense, Net	$2.580M	$81.00K
YoY Change	711.32%	-59.3%
Pretax Income	-$1.836M	-$5.817M	-$12.58M
YoY Change	-62.6%	58.89%	186.53%
Income Tax
% Of Pretax Income
Net Earnings	-$1.836M	-$5.817M	-$12.58M
YoY Change	-62.6%	58.89%	186.53%
Net Earnings / Revenue	-3672.0%	-14542.5%	-19347.69%
Basic Earnings Per Share	-$0.03	-$0.12
Diluted Earnings Per Share	-$0.03	-$0.12	-$0.26
COMMON SHARES
Basic Shares Outstanding	51.28M shares	49.90M shares	48.84M shares
Diluted Shares Outstanding	52.84M shares	49.46M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.06M	$10.94M	$13.07M
YoY Change	-64.57%	-64.53%	-61.77%
Cash & Equivalents	$3.554M	$3.295M	$5.439M
Short-Term Investments	$6.507M	$7.647M	$7.631M
Other Short-Term Assets	$300.0K	$364.0K	$302.0K
YoY Change	-31.51%	-33.58%	-33.63%
Inventory
Prepaid Expenses
Receivables			$1.184M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.36M	$11.31M	$14.56M
YoY Change	-64.11%	-65.9%	-59.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$109.0K	$118.0K	$824.0K
YoY Change	-24.83%	-23.87%	322.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.054M	$1.688M	$1.688M
YoY Change	15.13%	15.85%	40.43%
Total Long-Term Assets	$5.354M	$4.883M	$4.825M
YoY Change	12.76%	13.51%	15.79%
TOTAL ASSETS
Total Short-Term Assets	$10.36M	$11.31M	$14.56M
Total Long-Term Assets	$5.354M	$4.883M	$4.825M
Total Assets	$15.72M	$16.19M	$19.38M
YoY Change	-53.25%	-56.79%	-52.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.455M	$6.567M	$6.443M
YoY Change	153.6%	581.93%	1609.02%
Accrued Expenses	$799.0K	$1.446M	$2.209M
YoY Change	51.33%	107.76%	174.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.354M	$1.623M
YoY Change
Total Short-Term Liabilities	$8.842M	$9.876M	$8.652M
YoY Change	206.48%	437.62%	535.71%
LONG-TERM LIABILITIES
Long-Term Debt	$283.0K	$950.0K	$0.00
YoY Change
Other Long-Term Liabilities	$488.0K	$537.0K	$495.0K
YoY Change	-18.26%	-15.57%	-24.89%
Total Long-Term Liabilities	$283.0K	$950.0K	$495.0K
YoY Change	-52.6%	49.37%	-24.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.842M	$9.876M	$8.652M
Total Long-Term Liabilities	$283.0K	$950.0K	$495.0K
Total Liabilities	$9.613M	$11.36M	$9.147M
YoY Change	176.08%	359.48%	352.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$417.2M	-$415.3M	-$409.5M
YoY Change	7.21%	8.1%	7.61%
Common Stock	$57.00K	$50.00K	$49.00K
YoY Change	18.75%	4.17%	2.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.102M	$4.826M	$10.23M
YoY Change
Total Liabilities & Shareholders Equity	$15.72M	$16.19M	$19.38M
YoY Change	-53.25%	-56.79%	-52.13%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$1.836M	-$5.817M	-$12.58M
YoY Change	-62.6%	58.89%	186.53%
Depreciation, Depletion And Amortization	$61.00K	$9.000K	$58.00K
YoY Change	-23.75%	-18.18%	-65.88%
Cash From Operating Activities	-$3.008M	-$4.815M	-$9.758M
YoY Change	39.39%	30.84%	60.78%
INVESTING ACTIVITIES
Capital Expenditures			$198.0K
YoY Change			13.14%
Acquisitions
YoY Change
Other Investing Activities	$826.0K	-$158.0K	-$16.00K
YoY Change	-82700.0%	102.56%	-100.45%
Cash From Investing Activities	$826.0K	-$158.0K	-$214.0K
YoY Change	-504.9%	102.56%	-106.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.441M	$2.829M	147.0K
YoY Change	48720.0%	2729.0%
NET CHANGE
Cash From Operating Activities	-3.008M	-$4.815M	-9.758M
Cash From Investing Activities	826.0K	-$158.0K	-214.0K
Cash From Financing Activities	2.441M	$2.829M	147.0K
Net Change In Cash	259.0K	-$2.144M	-9.825M
YoY Change	-110.99%	-41.39%	263.08%
FREE CASH FLOW
Cash From Operating Activities	-$3.008M	-$4.815M	-$9.758M
Capital Expenditures			$198.0K
Free Cash Flow			-$9.956M
YoY Change			59.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity File Number EntityFileNumber	001-27072
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	AIM IMMUNOTECH INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-0845822
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2117 SW Highway 484
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocala
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34473
CY2024Q1	dei	City Area Code CityAreaCode	(352)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	448-7797
CY2024Q1	dei	Trading Symbol TradingSymbol	AIM
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Manufacturing Costs ManufacturingCosts		usd
CY2023Q1	us-gaap	Interest Expense InterestExpense		usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2024Q1	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q1	AIM	Committed Shares In Value CommittedSharesInValue		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2024Q1	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2024Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2024Q1	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred		usd
CY2024Q1	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments		usd
CY2024Q1	AIM	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet		usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization		usd
CY2024Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized		usd
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized		usd
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Loan Processing Fee LoanProcessingFee		usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51281437	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3295000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7647000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1184000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	364000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	11306000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	763000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2314000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1688000	usd
CY2024Q1	us-gaap	Assets Assets	16189000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6567000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1446000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1623000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9876000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	537000	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	950000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	11363000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50251933	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50251933	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49102484	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	50000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	419412000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-415325000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4826000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16189000	usd
CY2024Q1	us-gaap	Revenues Revenues	40000	usd
CY2023Q1	us-gaap	Revenues Revenues	49000	usd
CY2024Q1	us-gaap	Manufacturing Costs ManufacturingCosts	8000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1951000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2052000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3815000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2292000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	5774000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	4344000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5734000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4295000	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-92000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	203000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	81000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	199000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	72000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-23000	usd
CY2023Q1	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-255000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5817000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3661000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49458023	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49458023	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48399950	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48399950	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10234000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	329000	usd
CY2024Q1	AIM	Proceeds From Issuance Of Warrants Shares ProceedsFromIssuanceOfWarrantsShares	3272	shares
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80000	usd
CY2024Q1	AIM	Committed Shares In Shares CommittedSharesInShares	338600	shares
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5817000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4826000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3661000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5817000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3661000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	9000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	11000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	73000	usd
CY2024Q1	AIM	Noncash Lease Expense NoncashLeaseExpense	-67000	usd
CY2023Q1	AIM	Noncash Lease Expense NoncashLeaseExpense	37000	usd
CY2023Q1	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-255000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	80000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	82000	usd
CY2024Q1	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-92000	usd
CY2023Q1	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	203000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1184000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	62000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	180000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	60000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-23000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	124000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	586000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-540000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-110000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4815000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3680000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	50000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	598000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	158000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	712000	usd
CY2024Q1	AIM	Proceeds From Payments To Acquire Intangible Assets ProceedsFromPaymentsToAcquireIntangibleAssets	50000	usd
CY2023Q1	AIM	Proceeds From Payments To Acquire Intangible Assets ProceedsFromPaymentsToAcquireIntangibleAssets	-7000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	29000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-158000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	329000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	100000	usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2829000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2144000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3658000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5439000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3295000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23395000	usd
CY2023Q1	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	4000	usd
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7647000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7631000	usd
CY2024Q1	us-gaap	Marketable Securities MarketableSecurities	7647000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	7647000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-92000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-20000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-72000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	7631000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	7631000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	290000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-87000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	203000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1448000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1448000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1330000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1321000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	9000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	11000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3226000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-912000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2314000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-863000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2024Q1	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	50000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2314000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	186000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	237000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	235000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	212000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	193000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1251000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2314000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	763000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	777000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	718000	usd
CY2024Q1	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	296000	usd
CY2023Q4	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	363000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	74000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	68000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	49000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	19000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	123000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	87000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	123000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	87000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P39M
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P41M
CY2024Q1	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.10	pure
CY2023Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.10	pure
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2573000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1623000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	950000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	229000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	273000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	244000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	159000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	128000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	777000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	205000	shares
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	451000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	414000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	881000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1352000	usd
CY2024Q1	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	103000	usd
CY2023Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	184000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1446000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1986000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	3330000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-738000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	19000	usd
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	29000	usd
CY2024Q1	us-gaap	Interest Costs Incurred InterestCostsIncurred	29000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	43000	usd
CY2024Q1	us-gaap	Loan Processing Fee LoanProcessingFee	1000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	44000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1250000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2080000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	3330000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	2000000000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	367000000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	10000000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	1330000000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	371000000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9000000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.20
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	114	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.80
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q1	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50251933	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	152160	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	80000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	82000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	214000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	134000	usd

Files In Submission

Name	View Source	Status
0001493152-24-019917-index-headers.html	Edgar Link	pending
0001493152-24-019917-index.html	Edgar Link	pending
0001493152-24-019917.txt	Edgar Link	pending
0001493152-24-019917-xbrl.zip	Edgar Link	pending
aim-20240331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
aim-20240331_lab.xml	Edgar Link	unprocessable
aim-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aim-20240331_cal.xml	Edgar Link	unprocessable
aim-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2024 Q2 Form 10-Q Financial Statement

#000149315224019917 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2024 Q2 Form 10-Q Financial Statement

#000149315224019917 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim